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Objectives The purpose of this study was to determine whether the timing of the most recent cardiac implantable elec-
tronic device (CIED) procedure, either a permanent pacemaker or implantable cardioverter-defibrillator, influ-
ences the clinical presentation and outcome of lead-associated endocarditis (LAE).
Background The CIED infection rate has increased at a time of increased device use. LAE is associated with significant
morbidity and mortality.
Methods The clinical presentation and course of LAE were evaluated by the MEDIC (Multicenter Electrophysiologic Device
Cohort) registry, an international registry enrolling patients with CIED infection. Consecutive LAE patients en-
rolled in the Multicenter Electrophysiologic Device Cohort registry between January 2009 and May 2011 were
analyzed. The clinical features and outcomes of 2 groups were compared based on the time from the most re-
cent CIED procedure (early, 6 months; late, 6 months).
Results The Multicenter Electrophysiologic Device Cohort registry entered 145 patients with LAE (early  43, late  102).
Early LAE patients presented with signs and symptoms of local pocket infection, whereas a remote source of
bacteremia was present in 38% of patients with late LAE but only 8% of early LAE (p  0.01). Staphylococcal
species were the most frequent pathogens in both early and late LAE. Treatment consisted of removal of all
hardware and intravenous administration of antibiotics. In-hospital mortality was low (early  7%, late  6%).
Conclusions The clinical presentation of LAE is influenced by the time from the most recent CIED procedure. Although clinical
manifestations of pocket infection are present in the majority of patients with early LAE, late LAE should be con-
sidered in any CIED patient who presents with fever, bloodstream infection, or signs of sepsis, even if the device
pocket appears uninfected. Prompt recognition and management may improve outcomes. (J Am Coll Cardiol
2012;59:681–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.011Implantation of cardiac implantable electronic devices
(CIEDs), both permanent pacemakers and implantable
cardioverter-defibrillators (ICDs), has dramatically in-
creased (1,2). This increase has been driven by the needs of
an aging population coupled with the expanded indications
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been increasing (6–8). Device infection is associated with
significant financial costs, morbidity, and mortality, requir-
ing aggressive treatment (9,10). Infection can present as
either local involvement at the device pocket or a systemic
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bloodstream infection, with or
without lead and valve endocar-
ditis. The clinical presentation
of lead-associated endocarditis
(LAE) is variable (9,11–14). In
the present analysis, we sought to
determine whether the timing of
the most recent CIED procedure
influences the clinical presenta-
tion and outcome of LAE.
Methods
The MEDIC (Multicenter Electrophysiologic Device In-
fection Cohort) registry is an international registry consist-
ing of 10 academic medical centers (see Online Appendix
for a list of enrolling centers) that prospectively enroll
patients with CIED infections. We analyzed patients with a
diagnosis of LAE who were enrolled in the MEDIC
registry between January 2009 and May 2011. The present
study was conducted to determine whether the time from
the most recent CIED procedure influences the risk factors,
clinical presentation, and microbiology of LAE. The local
institutional review board at each site approved the study
protocol. Patients were followed for 6 months after enroll-
ment in the MEDIC registry. Patient demographic, clinical,
and laboratory data at the time of LAE diagnosis and
treatment outcomes were entered into the MEDIC registry
database.
Definitions. The diagnosis of LAE was based on the
odified Duke criteria (10,15). LAE was present if there
as persistent bloodstream infection, documented by posi-
ive blood cultures and the presence of lead vegetation
ocumented by echocardiography. Patients with unex-
lained fever and persistent unexplained bloodstream infec-
ion in the absence of a documented intracardiac vegetation
ere also included in the analysis if their symptoms resolved
fter removal of a CIED. Another group of patients with
AE were those patients with an unexplained intracardiac
egetation who presented with local pocket or systemic
ymptoms but had already been treated with antibiotics.
A vegetation was defined as an oscillating intracardiac
ass on a pacemaker or ICD lead or cardiac valve that was
resent in 1 echocardiographic plane. Early LAE was
efined as signs and symptoms that occurred within 6
onths of the most recent CIED procedure. If LAE signs
nd symptoms occurred 6 months after surgery, it was
defined as late LAE.
The time from the most recent CIED procedure was
measured in months. A revision procedure included a pulse
generator replacement, lead revision, and system upgrade.
The initial implantation was defined as the first CIED
procedure. All subsequent procedures were, therefore, clas-
Abbreviations
and Acronyms
CIED  cardiac implantable
electronic device
CoNS  coagulase-negative
staphylococci
ICD  implantable
cardioverter-defibrillator
LAE  lead-associated
endocarditissified as revisions.To assess medical comorbid conditions, we used the
Charlson Comorbidity Index, which consists of 19 different
disease comorbidity categories, weighted from 1 to 6 based
on adjusted relative risk of 1-year mortality and summed to
provide a total score (16). The Charlson Comorbidity Index
was previously validated as a predictor of mortality in
patients with a permanent pacemaker (17).
Diagnosis and treatment. Multiple blood cultures were
obtained in each patient. The diagnosis of an intracardiac
vegetation was made by either transthoracic or transesoph-
ageal echocardiography. All patients underwent either per-
cutaneous or open surgical removal of all hardware. Lead
and pulse generator pocket cultures were obtained. After the
procedure, the patients received a prolonged course of
intravenous antibiotics based on published guidelines (10).
Reimplantation was performed at the discretion of the
primary physician. Patients were followed for 6 months
from the date of enrollment. A relapse was defined as a
recurrence of infection with the same organism based on
antimicrobial sensitivity.
Statistical analysis. Summary statistics (mean  SD, me-
dian, interquartile range, and frequency distribution) were
generated for patient demographic information and base-
line clinical presentation to characterize the study popu-
lation. A chi-square test or Fisher exact test was used to
compare categorical variables between early and late LAE
patients. Continuous variables were compared using a
2-sample t test or Wilcoxon sum rank test, as appropriate.
ll tests were 2-sided, and a p value 0.05 was considered
tatistically significant.
esults
atient demographics. A total of 145 patients with LAE
ere prospectively identified and enrolled in the MEDIC
egistry. Forty-three cases of LAE occurred within 6
onths of a CIED procedure and were classified as early
AE, whereas the remaining 102 cases occurred6 months
fter a CIED procedure and were classified as late LAE.
he patient demographics of the 2 groups are summarized
Patient DemographicsTable 1 Patient Demographics
Early
(n  43)
Late
(n  102) p Value
Age, yrs 66 15 63 16 NS
Male 74.4 67.6 NS
PM/ICD 15 (35)/28 (65) 50 (4)/52 (51) NS
Most recent procedure 0.03
Initial implantation 15 (35) 56 (55)
Revision 28 (65) 46 (45)
Months from most
recent procedure
1.9 (1, 3.5) 26.2 (17, 41.2)
No. of leads 2.4 0.8 2.4 0.87 NS
Ejection fraction, % 34.5 17.6 32.7 15.2 NS
Vegetation size, mm 8.5 (4.2, 17.2) 10 (5, 20) NSValues are mean  SD, %, n (%), or median (25th, 75th percentile).
ICD  implantable cardioverter-defibrillator; PM  permanent pacemaker.
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February 14, 2012:681–7 Timing of Lead-Associated Endocarditisin Table 1. The groups were similar with respect to age, sex,
and type of CIED, although early LAE patients had a
higher percentage of ICDs (65% vs. 51%, p  NS). The
most recent CIED procedure in early LAE patients was a
system revision in 28 of 43 (65%) compared with 46 of 102
of late LAE patients (45%) (p  0.03). More than half of
late LAE patients (55%) had a single procedure, which was
their initial CIED implantation. The total number of CIED
procedures was similar for both groups (2 1 vs. 1.7 0.91, p
NS). There was a history of CIED infection in 16% of early
LAE patients and 9% of late LAE patients.
The groups were similar with respect to major comorbid
conditions (Table 2) except that a higher percentage of late
LAE patients were on hemodialysis (early  5% vs. late 
19%, p  0.037). Multiple medical comorbid conditions
ere present in a majority of the study population. The
harlson Comorbidity index score was similar in the 2
roups (3 2.25 vs. 3 2.46, pNS). The most common
omorbidity was heart failure. The mean left ventricular
jection fraction was 34.5  17.6% in the early LAE group
nd 32.7  15.2% in the late LAE group (p  NS).
The presenting symptoms of LAE differed based on the
ime from the most recent CIED procedure (Table 3).
atients with early LAE more frequently presented with
igns of local pocket infection that included erythema, pain,
welling, warmth, and pus or drainage from the pocket. In
ontrast, the majority of patients with late LAE had signs of
ystemic infection, such as fever, chills or sweats, and signs
f sepsis. Peripheral emboli and signs of metastatic infection
ere seen infrequently and were not different between the 2
roups. There was echocardiographic evidence of lead
egetation in 63% of early LAE patients compared with
2% of late LAE patients (p  0.01). The patients without
vegetation were diagnosed with LAE because they had
persistent bloodstream infection without an identifiable
cause and their symptoms resolved once their CIED hard-
ware was removed. In early LAE patients, the lead vegeta-
tion was detected by transthoracic echocardiography in 11
of 43 (26%), whereas transesophageal echocardiography was
required in 16 of 43 (37%). No vegetation was seen by either
Patient ComorbiditiesTable 2 Patient Comorbidities
Early
(n  43)
Late
(n  102) p Value
CABG surgery 11 (26) 28 (28) NS
Heart failure 15 (33.3) 22 (22) NS
Hemodialysis 2 (5) 19 (19) 0.037
Prosthetic valve 6 (14) 12 (12) NS
Anticoagulation 13 (30) 21 (21) NS
Immunosuppressive use 3 (7) 4 (4) NS
Steroid use 3 (7) 4 (4) NS
Implanted central catheter 4 (9) 20 (20) NS
Vascular graft 4 (9) 12 (12) NS
Charlson Comorbidity Index 3 2.25 3 2.46 NSp
Values are n (%) or mean  SD.
CABG  coronary artery bypass graft.modality in 37%. In contrast, in late LAE patients, trans-
thoracic echocardiography detected the vegetation in only
23 of 102 (23%), whereas transesophageal echocardiography
was required in 60 of 102 patients (59%) to detect the lead
vegetation. The remaining 18% had no vegetation detected.
The median vegetation size was similar in both groups (early 
8.5 mm vs. late  10 mm). In addition, a vegetation was
present on an intracardiac valve in 18 of 43 (42%) early LAE
patients and 31 of 102 late LAE patients (29%). In early
LAE patients, there was evidence of a vegetation on the
aortic valve in 4 (21%), the mitral valve in 6 (32%), the
tricuspid valve in 6 (32%), and the pulmonic valve in 2
(15%). In contrast, late LAE patients had evidence of a
vegetation on the aortic valve in 5 (16%), the mitral valve in
6 (19%), the tricuspid valve in 18 (58%), and the pulmonic
valve in 2 (7%).
The source of the bloodstream infection differed between
the groups (Fig. 1). The CIED wound or CIED device site
was commonly identified as the source of infection in early
LAE (54%); this was not the case in late LAE (11%, p 
0.001). A remote source of infection, such as a vascular
catheter (4%) and the gastrointestinal tract (1%), was
identified in a minority (8%) of early LAE patients. In
contrast, late LAE patients more commonly had a remote
source of infection identified (38%, p  0.01). Remote
ources of infection included vascular catheters (15%),
nfected atrioventricular fistulae (4%), localized abscess
3%), and osteomyelitis (6%).
acteriology. Blood cultures were positive in 31 of 43 early
AE patients (72%) and 95 of 102 late LAE patients (93%).
IED pocket cultures were positive in 25 of 39 early LAE
atients (62%) compared with 30 of 89 of late LAE patients
34%) (p  0.011). No pocket culture was obtained in 4
early LAE patients and 13 late LAE patients. Lead cultures
were positive in 24 of 39 early LAE patients (62%) and 40
of 88 late LAE patients (46%) (p  NS). No lead culture
as obtained in 4 early LAE patients and 14 late LAE
Presenting SymptomsTable 3 Presenting Symptoms
Early
(n  43)
Late
(n  102) p Value
Signs of local infection
Erythema 19 (44) 11 (11) 0.001
Pain 16 (37) 14 (14) 0.004
Swelling 16 (37) 9 (9) 0.001
Warmth 17 (40) 7 (7) 0.001
Pus 9 (21) 4 (4) 0.003
Drainage 12 (28) 6 (6) 0.001
Signs of systemic infection
Fever 38°C 26 (61) 82 (80) 0.02
Chills/sweats 25 (58) 80 (78) 0.03
Sepsis 13 (30) 48 (47) 0.05
Peripheral signs
Emboli 3 (7) 14 (14) NS
Values are n (%).atients. Staphylococci were the most frequent pathogens in
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of early LAE patients and 67% of late LAE patients (p 
NS). Staphylococcus aureus was the most common cause of
LAE (15 of 43 early LAE vs. 42 of 102 late LAE), followed
by the coagulase-negative staphylococci (CoNS) (7 of 43
early LAE vs. 25 of 102 late LAE) and streptococci.
Methicillin resistance was present in 5 of 15 early LAE
patients (30%) and 18 of 42 late LAE patients (23%)
infected with S. aureus. No organism could be cultured in
8% of the early LAE patients and 5% of the late LAE
atients.
utcome. The CIED device and leads were removed at
he time of presentation in all cases. A laser sheath was
equired for lead removal in 56% of early LAE patients and
4% of late LAE patients. The entire system was success-
ully removed in all but 2 of 43 (5%) early LAE patients and
of 102 late LAE patients (4%) (p  NS). Some residual
lead material remained in the 2 early LAE patients and 4
Figure 1 Source of Bloodstream Infection
The time from the most recent cardiac implantable electronic device procedure infl
site in 54% of early lead-associated endocarditis (LAE), but only 11% of late LAE (
but only 8% of early LAE patients (p  0.01). AV  atrioventricular.
Figure 2 Microbiology of Lead-Associated Endocarditis
CoNS  coagulase-negative staphylococci; MRSA  methicillin-resistant
Staphylococcus aureus; MSSA  methicillin-sensitive Staphylococcus aureus.late LAE patients. No patient required conversion to open
thoracotomy. Pulmonary emboli after CIED removal oc-
curred in 1 early LAE patient (2.3%) and 6 late LAE
patients (6%). In-hospital mortality was 7% in the early
LAE group and 6% in the late LAE group. Patients were
treated with intravenous antibiotics for a median of 42 days
(25th, 75th percentiles: early LAE 34, 52 days, late LAE 30,
52 days). A new CIED device was implanted in 44% of the
early LAE group and 53% of the late LAE group. Complete
6-month follow-up data were available for 24 of 43 early
LAE patients (56%) and 63 of 102 late LAE patients (62%).
One patient in each group had recurrent LAE. Six-month
mortality was 25% in early LAE patients and 29% in late
LAE patients.
Discussion
Our evaluation of a large, prospective, multicenter cohort of
patients with LAE provides significant insights that include
the following: 1) the clinical presentation of LAE is
influenced by the time from the most recent CIED proce-
dure; 2) patients in whom LAE develops within 6 months
of a CIED procedure usually present with signs and
symptoms associated with local CIED pocket site infection;
3) LAE may develop months or years after a CIED
procedure; 4) patients who present with signs and symptoms
of systemic infection often have identifiable remote sites of
infection; 5) in-hospital mortality is 6% to 7%; and 6) the
recurrence rate is low in surviving patients.
Increasing CIED infection burden. The CIED implan-
tation rate has dramatically increased over the past 2
decades, driven by the increase in ICD use (1,2,6). Recent
data suggest that although overall complications associated
with CIED implantation have decreased, the infection
burden has increased (7,8,18–20). Infection after CIED
d the source of bacteremia. The source of bacteremia was a wound or device
001). A remote source of bacteremia was present in 38% of late LAE patientsuence
p  0.implantation remains a major complication with significant
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February 14, 2012:681–7 Timing of Lead-Associated Endocarditismorbidity and mortality, coupled with tremendous financial
costs (21).
Clinical presentation of LAE: early versus late. CIED
nfection may present as either local CIED pocket infection
r systemic bloodstream infection associated with LAE.
rompt recognition and treatment of CIED infection are
mperative because morbidity and mortality remain high
ith untreated infection. Effective treatment of CIED
nfection, either local or systemic infection, requires removal
f all hardware.
LAE represents 19% to 23% of total CIED infections
22,23). Although LAE may occur soon after a CIED
rocedure, patients with LAE can present months or years
ater. It is not known why systemic infection and LAE
evelop in a limited number of patients with local CIED
nfection. Previous studies have emphasized the importance
f patient comorbid conditions including multiple device
evisions in LAE predisposition (9–13,24,25). Another
ontributing factor may be a delay in the optimal man-
gement of local pocket infection. Many of our patients
ith early LAE received antibiotics for some time before
heir transfer to a MEDIC center for removal of all
IED hardware. The duration of previous antibiotic
herapy is not known. A recent study showed that a delay
n CIED removal is associated with increased morbidity
nd mortality (26).
The present analysis demonstrates that the time from the
ost recent CIED procedure influences the clinical presen-
ation of LAE. Patients in whom LAE develops soon after
CIED procedure often present with signs of local inflam-
ation with bacteremia due to the organism responsible for
he local infection. In our study, the median time from the
ost recent procedure was 1.9 months. Klug et al. (11)
ound that 14 of 52 patients (27%) with pacemaker LAE
resented within 6 weeks of their last pacemaker-related
rocedure. Signs of local pocket inflammation were evident
mean of 4 days post-procedure. Differences in patient
emographics may explain a disparity in the timing and
linical presentation of early LAE.
By contrast, the majority of our patients with late LAE
resented with signs of systemic infection such as fever,
hills, sweats, and signs of sepsis. Infection presented a
edian of 26.2 months after the most recent procedure.
emote sources of infection were common. In our patients
ith late LAE, 6% had vascular catheters such as peripheral
r central intravenous catheters, 9% had permanent hemo-
ialysis catheters, and 4% had atrioventricular fistulae as the
ikely remote source of bacteremia. In addition, 19% of
atients had an identifiable noncatheter-related source of
acteremia such as an abscess and osteomyelitis remote from
he pulse generator site. Patients with late LAE had
ultiple medical comorbid conditions including the high
revalence of long-term hemodialysis in 19% of the cases.
he frequent need for vascular access is likely a contributingactor. LBacteriology and diagnosis of LAE. In our series, S.
aureus was the most common pathogen isolated in both
early and late LAE, consistent with previous publications
that reported that staphylococcal species were the predom-
inant organisms responsible for LAE in more than two
thirds of cases (9,11,13). Earlier investigators have also
demonstrated that CIED recipients with S. aureus bactere-
mia are particularly at high risk of LAE (27–29). This
association is likely due to hematogenous seeding of the
CIED device after S. aureus bacteremia. It further under-
scores the importance of managing vascular access catheters
in CIED patients because these may represent portals for
bacteremia. Earlier investigations have also highlighted the
role of drug-resistant pathogens in LAE (30). In our series,
methicillin-resistant S. aureus was responsible for 16% of
LAE (early  12%, late  18%). However, LAE was also
aused by organisms other than S. aureus. Skin flora, such as
oNS, are common pathogens isolated in LAE. In 1 series,
IED infection was present in 36% of patients with CoNS
acteremia and 20% of non–S. aureus gram-positive cocci
31). Therefore, LAE should be considered in any CIED
atient in whom gram-positive bacteremia develops, regard-
ess of the organism.
In general, a diagnosis of LAE relies on the finding of an
ntracardiac vegetation on echocardiography and documen-
ation of persistent bloodstream infection (10). Transesoph-
geal echocardiography is often required to make the
iagnosis (9,14,32). However, LAE should also be consid-
red in CIED patients who have persistent bacteremia
ithout an identifiable source, even if the echocardiogram is
nconclusive. In our study, 38% of early and 18% of late
AE patients had no vegetation detectable by either trans-
horacic or transesophageal echocardiography. However,
linical manifestations of infection resolved in all these
atients on complete removal of CIED hardware and with
ystemic antibiotic therapy, suggesting underlying device
nfection. Consequently, the importance of obtaining blood
ultures in any patient with a CIED who presents with signs
nd symptoms of pocket infection or a systemic illness
annot be overemphasized. Transesophageal echocardiogra-
hy should be pursued if the findings on transthoracic
maging are negative or inconclusive. This is especially
mportant in CIED recipients who present with unex-
lained fever or bacteremia without a clear source.
reatment of LAE. Treatment of LAE requires removal
f all CIED hardware and a prolonged course of intrave-
ous antibiotics (9–11,13,14). Lead removal can be accom-
lished in 95% of cases without the need for open heart
urgery (10,33). The LEXICON (Lead Extraction in the
ontemporary Setting) study evaluated the safety and effi-
acy of laser-assisted lead extraction in a diverse group of
,149 consecutive patients. The indication for lead extrac-
ion was CIED infection in 56.9%, including 29.2% who
ad LAE. Clinical success was achieved in 98.8%, with a
ajor adverse event rate of 4.0%. However, mortality in the
AE group was 4.3% despite CIED removal. In our series
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death and few other serious sequelae such as pulmonary
emboli, despite removing leads percutaneously with vegeta-
tions that averaged 10 mm in diameter. Prolonged treat-
ment of LAE with systemic antibiotics is recommended
(10), although a shorter duration of treatment is possible if
endocarditis is confined to the right heart (9). With modern
aggressive therapy, reported in-hospital mortality from
LAE ranges from 4% to 7% (9–11,13,14). Mortality, in
part, depends on the causative agent, as LAE caused by S.
aureus is associated with a poorer outcome compared with
CoNS.
Many patients undergoing CIED extraction for infection
require ongoing device therapy, and reimplantation of a new
CIED is warranted. The optimal timing of device reim-
plantation in patients with LAE has not been determined.
In general, most experts believe that a CIED device may be
reimplanted in infected patients once the CIED has been
removed and blood cultures are consistently negative (9).
However, a longer waiting time may be reasonable in
patients with valvular endocarditis.
Study limitations. The decision to use the 6-month time
point to define early versus late LAE was arbitrary. It is
possible that other time points could be used for analysis.
Nonetheless, the use of the 6-month definition did provide
useful information to distinguish the clinical presentations
of early versus late LAE. Our analysis included patients who
had persistent bloodstream infection without evidence of an
intracardiac vegetation because their symptoms resolved
after removal of their CIED. Previous investigation showed
that the 1-year mortality of patients with bloodstream
infection is similar to those with documented vegetations
(26). We recognize that the patient population studied
reflects those referred to academic medical centers for
treatment and may not be representative of all patients with
LAE. In addition, 6-month follow-up data were not avail-
able for all patients because many patients were referred to
the study centers for initial treatment of LAE but returned
to their local medical centers for continued care. Our data
may, therefore, underestimate both the true LAE relapse
rate and 6-month mortality rate.
Conclusions
LAE is a serious complication of CIED implantation that is
associated with considerable morbidity and mortality. Com-
plete CIED removal is necessary for attempted cure, which
also involves prolonged antimicrobial therapy. The clinical
presentation of LAE is influenced by the time from the
most recent CIED procedure. Although clinical manifesta-
tions of pocket infection are present in the majority of
patients with early LAE, late-onset LAE should be consid-
ered in all CIED patients who present with fever, blood-
stream infection, or signs of sepsis even if the device pocket
is ostensibly uninfected. Prompt recognition and manage-
ment may improve clinical outcomes.Reprint requests and correspondence: Dr. Arnold J. Green-
spon, Cardiac Electrophysiology Laboratory, Thomas Jefferson
University Hospital, Jefferson Heart Institute, 925 Chestnut
Street, Mezzanine, Philadelphia, Pennsylvania 19107. E-mail:
arnold.greenspon@jefferson.edu.
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